Business Description
Mira Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
MIRA.USA IPO Date
2023-08-03Description
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.72 | |||||
| Equity-to-Asset | -0.7 | |||||
| Debt-to-Equity | -0.82 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.46 | |||||
| 9-Day RSI | 29.83 | |||||
| 14-Day RSI | 36.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.36 | |||||
| Quick Ratio | 0.36 | |||||
| Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -847.81 | |||||
| ROA % | -335.06 | |||||
| ROIC % | -934.13 | |||||
| ROC (Joel Greenblatt) % | -1936.26 | |||||
| ROCE % | -805.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -3 | |||||
| EV-to-EBITDA | -3 | |||||
| EV-to-FCF | -3.77 | |||||
| Earnings Yield (Greenblatt) % | -33.33 | |||||
| FCF Yield % | -27.83 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIRA
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mira Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.479 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 36.03 | ||
| 14-Day ATR ($) | 0.674237 | ||
| 20-Day SMA ($) | 3.000495 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 1.33 - 7.9799 | ||
| Shares Outstanding (Mil) | 14.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mira Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mira Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mira Pharmaceuticals Inc Frequently Asked Questions
What is Mira Pharmaceuticals Inc(MIRA)'s stock price today?
The current price of MIRA is $1.58. The 52 week high of MIRA is $7.98 and 52 week low is $1.33.
When is next earnings date of Mira Pharmaceuticals Inc(MIRA)?
The next earnings date of Mira Pharmaceuticals Inc(MIRA) is 2024-02-29 Est..
Does Mira Pharmaceuticals Inc(MIRA) pay dividends? If so, how much?
Mira Pharmaceuticals Inc(MIRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers